| Autor: |
McCoy, J., Wambier, C.G., Herrera, S., Vaño‐Galván, S., Gioia, F., Comeche, B., Ron, R., Serrano‐Villar, S., Iwasiow, R.M., Tayeb, M.A., Cadegiani, F.A., Mesinkovska, N.A., Shapiro, J., Sinclair, R., Goren, A. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2021, Vol. 35 Issue 1, pe15-e17, 3p |
| Abstrakt: |
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients Men infected with SARS-CoV-2 are more likely to be admitted to the intensive care unit (ICU) compared with women.1 Previously, we have reported that among hospitalized men with COVID-19, 79% presented with androgenetic alopecia (AA) compared with 31-53% that would be expected in a similar aged match population.2 AA is known to be mediated by variations in the androgen receptor ( I AR i ) gene.3 In addition, the only known promoter of the enzyme implicated in SARS-CoV-2 infectivity, transmembrane protease, serine 2, is regulated by an androgen response element.4 The polyglutamine repeat (CAG repeat) located in the I AR i gene is associated with androgen sensitivity and AA.3 These observations led us to hypothesize that variations in the I AR i gene may predispose male COVID-19 patients to increased disease severity. We recognize the limitations of this small study; however, our findings, combined with previous reports implicating androgens in COVID-19 disease severity,3-5 should encourage other groups to explore interventional studies of anti-androgens in COVID-19-infected patients. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text